Raymond James analyst Steven Seedhouse downgraded Q32 Bio (QTTB) to Outperform from Strong Buy with a price target of $22, down from $90, following the Phase 2 data update for bempikibart. The firm says it underestimated the negative market reaction in “this mixed data scenario” but still believes the company’s IL7R-4 mechanism “is not a zero.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTTB:
- Q32 Bio downgraded to Equal Weight from Overweight at Wells Fargo
- Q32 Bio reports results from SIGNAL-AA Phase 2a clinical trial
- Q32 Bio initiated with an Outperform at BMO Capital
- Q32 Bio Advances Clinical Trials Amidst Financial Challenges
- Q32 Bio Inc Grapples with Internal Control Challenges Amid Compliance Costs
Questions or Comments about the article? Write to editor@tipranks.com